| Dr Ramandeep S Gakhal, MD | |
|
701 Dellwood St S, Cambridge, MN 55008-1920 | |
| (763) 689-8700 | |
| Not Available |
| Full Name | Dr Ramandeep S Gakhal |
|---|---|
| Gender | Male |
| Speciality | Psychiatry |
| Experience | 13 Years |
| Location | 701 Dellwood St S, Cambridge, Minnesota |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1134410293 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2084P0800X | Psychiatry & Neurology - Psychiatry | 58559 (Minnesota) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Abbott Northwestern Hospital | Minneapolis, MN | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Allina Health System | 4587573613 | 3071 |
News Archive
Silence Therapeutics plc announces the issuance of United States patent 7,772,203, titled "Methods and Compositions for Controlling Efficacy of RNA Silencing," by the United States Patent and Trademark Office (USPTO). The issued patent generally claims methods of enhancing RNA silencing with a double stranded RNA interference (RNAi) agent. The patent's RNA silencing method claims include coverage for the administering of a pharmaceutical composition containing short interfering RNA (siRNA), micro RNA (miRNA), pre-miRNA or short hairpin (shRNA) molecules. Silence believes the proprietary structural modification techniques covered in this patent will play a key role in increasing the potential therapeutic efficacy of RNAi therapeutics.
In his latest Kaiser Health News column, done in collaboration with The New Republic, Jonathan Cohn writes: "Everywhere you look, Medicaid seems to be in jeopardy.
Complex wounds affect more patients in the United States than heart attack and stroke combined. About 150,000 amputations a year result from complex wounds, while about 80,000 are attributed to diabetes and peripheral arterial disease. There are currently no established methods for early detection of wound healing, or for precise identification of healing progress.
Prisons are not taking appropriate action to improve diet and increase physical activity levels to help prevent noncommunicable diseases among prisoners, say UK researchers in The Lancet.
› Verified 6 days ago
| Entity Name | Allina Health System |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1295272342 PECOS PAC ID: 4587573613 Enrollment ID: O20040319000460 |
News Archive
Silence Therapeutics plc announces the issuance of United States patent 7,772,203, titled "Methods and Compositions for Controlling Efficacy of RNA Silencing," by the United States Patent and Trademark Office (USPTO). The issued patent generally claims methods of enhancing RNA silencing with a double stranded RNA interference (RNAi) agent. The patent's RNA silencing method claims include coverage for the administering of a pharmaceutical composition containing short interfering RNA (siRNA), micro RNA (miRNA), pre-miRNA or short hairpin (shRNA) molecules. Silence believes the proprietary structural modification techniques covered in this patent will play a key role in increasing the potential therapeutic efficacy of RNAi therapeutics.
In his latest Kaiser Health News column, done in collaboration with The New Republic, Jonathan Cohn writes: "Everywhere you look, Medicaid seems to be in jeopardy.
Complex wounds affect more patients in the United States than heart attack and stroke combined. About 150,000 amputations a year result from complex wounds, while about 80,000 are attributed to diabetes and peripheral arterial disease. There are currently no established methods for early detection of wound healing, or for precise identification of healing progress.
Prisons are not taking appropriate action to improve diet and increase physical activity levels to help prevent noncommunicable diseases among prisoners, say UK researchers in The Lancet.
› Verified 6 days ago
| Entity Name | Allina Health System |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1457657249 PECOS PAC ID: 4587573613 Enrollment ID: O20221213001713 |
News Archive
Silence Therapeutics plc announces the issuance of United States patent 7,772,203, titled "Methods and Compositions for Controlling Efficacy of RNA Silencing," by the United States Patent and Trademark Office (USPTO). The issued patent generally claims methods of enhancing RNA silencing with a double stranded RNA interference (RNAi) agent. The patent's RNA silencing method claims include coverage for the administering of a pharmaceutical composition containing short interfering RNA (siRNA), micro RNA (miRNA), pre-miRNA or short hairpin (shRNA) molecules. Silence believes the proprietary structural modification techniques covered in this patent will play a key role in increasing the potential therapeutic efficacy of RNAi therapeutics.
In his latest Kaiser Health News column, done in collaboration with The New Republic, Jonathan Cohn writes: "Everywhere you look, Medicaid seems to be in jeopardy.
Complex wounds affect more patients in the United States than heart attack and stroke combined. About 150,000 amputations a year result from complex wounds, while about 80,000 are attributed to diabetes and peripheral arterial disease. There are currently no established methods for early detection of wound healing, or for precise identification of healing progress.
Prisons are not taking appropriate action to improve diet and increase physical activity levels to help prevent noncommunicable diseases among prisoners, say UK researchers in The Lancet.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Ramandeep S Gakhal, MD 701 Dellwood St S, Cambridge, MN 55008-1920 Ph: (763) 689-8700 | Dr Ramandeep S Gakhal, MD 701 Dellwood St S, Cambridge, MN 55008-1920 Ph: (763) 689-8700 |
News Archive
Silence Therapeutics plc announces the issuance of United States patent 7,772,203, titled "Methods and Compositions for Controlling Efficacy of RNA Silencing," by the United States Patent and Trademark Office (USPTO). The issued patent generally claims methods of enhancing RNA silencing with a double stranded RNA interference (RNAi) agent. The patent's RNA silencing method claims include coverage for the administering of a pharmaceutical composition containing short interfering RNA (siRNA), micro RNA (miRNA), pre-miRNA or short hairpin (shRNA) molecules. Silence believes the proprietary structural modification techniques covered in this patent will play a key role in increasing the potential therapeutic efficacy of RNAi therapeutics.
In his latest Kaiser Health News column, done in collaboration with The New Republic, Jonathan Cohn writes: "Everywhere you look, Medicaid seems to be in jeopardy.
Complex wounds affect more patients in the United States than heart attack and stroke combined. About 150,000 amputations a year result from complex wounds, while about 80,000 are attributed to diabetes and peripheral arterial disease. There are currently no established methods for early detection of wound healing, or for precise identification of healing progress.
Prisons are not taking appropriate action to improve diet and increase physical activity levels to help prevent noncommunicable diseases among prisoners, say UK researchers in The Lancet.
› Verified 6 days ago
Jane Marie Achenbach, MD Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 701 Dellwood St S, Cambridge, MN 55008 Phone: 763-689-7700 | |
Boris L Kholomyansky, MD Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 701 Dellwood St S, Cambridge, MN 55008 Phone: 763-689-7700 | |
Dr. Erin Callahan Soto, M.D. Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 701 Dellwood St S, Cambridge, MN 55008 Phone: 763-689-7700 |